HEALTH ECONOMIC MODEL ON THE COSTS AND EFFECTS OF ROTAVIRUS VACCINATION IN ROMANIA
Author(s)
Preda AL1, Moise M1, Standaert B2
1GlaxoSmithKline, Bucharest, Romania, 2GlaxoSmithKline Vaccines, Wavre, Belgium
OBJECTIVES Rotavirus gastroenteritis (RVGE) is one of the most frequent diseases in children less than 5 years old. Today, no recommendation for general rotavirus vaccination exists in Romania, which leads to a vaccination coverage rate of < 8%. We model whether the strategy of “Universal Mass Vaccination” should be cost-effective from the Social Health Insurance Fund (SHIF) perspective. METHODS We adapted an already published simple model to estimate the cost-effectiveness of rotavirus vaccination in Romania. It helps identifying the drivers of the economic analysis in a birth cohort of 194,411 children (Romania 2012) followed over a period of 5 years. In the model, vaccine efficacy results from international clinical trials are combined with Romanian epidemiology and cost data from the SHIF perspective for 2012. The model assumes a theoretical vaccination rate of 100% and uses discount rates of 3% on costs and effects. Results are tested on their robustness using univariate sensitivity analysis. RESULTS The model predicts that a two-dose rotavirus vaccine could avoid around 82,581 mild, 51,328 moderate and 3,075 severe RVGE cases. Moderate and severe events are associated with physician visits and hospital stays respectively. These also lead to a total cost saving of € 2.4 million for indirect cost estimates. The main factors responsible for the savings are the reduction in hospital stays, in productivity losses of parents and in medical visits. Sensitivity analysis indicates the importance of good epidemiological data and cost numbers on productivity loss. CONCLUSIONS General vaccination against rotavirus could avoid many of the severe diarrhea events in children less than 5 years old in Romania. Depending on the price per course, the vaccination strategy will lead to societal cost gain.
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PIH29
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Pediatrics